Effects of nicotinic acid treatment on glyceride formation and lipolysis in adipose tissue of hyperlipidemic patients.
Thirty-one weight-stable patients with different types of hyperlipoproteinemia were treated daily with 4 g nicotinic acid for 6 weeks. Effects of this therapy on adipose tissue metabolism were evaluated. By using biopsy specimens of subcutaneous adipose tissue, fatty acid and glucose incorporation into adipose tissue glycerides were measured in vitro as well as glycerol and fatty acid release, which allowed us to estimate adipose tissue lipolysis. The amount of fatty acids produced by lipolysis and thereafter utilized within adipose tissue without being released (fatty acid retention) was estimated. Fatty acid and glucose incorporation into adipose tissue, glycerol release and fatty acid retention values increased, but serum triglyceride levels decreased (all P < 0.001) after nicotinic acid treatment. The change in fatty acid incorporation was positively correlated with changes in glucose incorporation into adipose tissue (r = 0.53, P < 0.01) and fatty acid retention (r = 0.76, P < 0.001). Although adipose tissue lipolysis, measured as glycerol release, increased, the lipolyzed fatty acids were retained in adipose tissue, suggesting an enhanced synthesis of glycerides both from exogenous and endogenous sources. The increase in fatty acid incorporation into adipose tissue indicates that the decrease in serum triglyceride levels produced by nicotinic acid treatment may partly be due to the fact that this drug promotes incorporation of fatty acids, derived from lipoprotein-carried triglycerides in the blood, into adipose tissue glycerides.
King Gustaf V Research Institute, Karolinska Hospital, Stockholm, Sweden.
G
G
Wahlberg
G
G
Walldius
D000273:Adipose Tissue / Q000187:drug effects* / Q000378:metabolism; D000328:Adult; D000368:Aged; D005227:Fatty Acids / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D005947:Glucose / Q000378:metabolism; D005989:Glycerides / Q000096:biosynthesis*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D008066:Lipolysis / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000494:pharmacology*
D005227:Fatty Acids; D005989:Glycerides; D009525:Niacin; D005947:Glucose